Discover

AMGN
Amgen Inc.
439.33
1 x 437.47
1 x 433.67
bid
ask
+
8.12
1.88%
1 @ 07:52 PM
439.80 +0.47 (0.11%)
Ytd34.22%
1y48.54%
429.38
day range
440.51
271.18
52 week range
442.36
Open431.71Prev Close431.21Low429.38High440.51Mkt Cap237.11B
Vol1.88MAvg Vol2.70MEPS16.30P/E26.95Forward P/E18.01
Beta0.41Short Ratio5.66Inst. Own85.12%Dividend10.08Div Yield2.32
Ex Div Date08-21Earning11-0350-d Avg376.93200-d Avg352.121yr Est388.48
Earning
DateForEstimateReportedSurprisesurprise %
2026-11-032026-095.79N/AN/AN/A
2026-08-042026-065.626.290.6711.92%
2026-04-302026-034.775.150.387.97%
2026-02-032025-124.735.290.5611.84%
2025-11-042025-095.025.640.6212.35%
2025-08-052025-065.286.020.7414.02%
Upgrade / Downgrade
DateFirmActionFromTo
2026-08-20Piper SandlerUpgradeOverweightOverweight
2026-08-19Argus ResearchUpgradeBuyBuy
2026-08-18MizuhoUpgradeNeutralNeutral
2026-08-18Cantor FitzgeraldUpgradeNeutralNeutral
2026-08-14BarclaysUpgradeEqual-WeightEqual-Weight
2026-08-10GuggenheimUpgradeNeutralNeutral
Profile
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Insider Holder
DateNameRelationQuantityDescription
2026-05-04BRADNER JAMES E.Officer30.46KStock Award(Grant)
2026-05-04BRADWAY ROBERT AChief Executive Officer657.30KStock Award(Grant)
2026-05-18ECKERT ROBERT ANDREWDirector26.25KStock Award(Grant)
2026-05-04GORDON MURDOOfficer51.84KStock Award(Grant)
2026-05-04GRAHAM JONATHAN PGeneral Counsel40.21KStock Award(Grant)
2026-05-04GRIFFITH PETER H.Chief Financial Officer50.71KStock Award(Grant)
Institution Ownership
Report DateOrganizationPositionValuePercentage
2026-06-29Blackrock Inc.49.36M21.69B9.13%
2026-06-29Vanguard Capital Management LLC35.25M15.49B6.52%
2026-06-29State Street Corporation30.56M13.43B5.65%
2026-06-29Capital World Investors29.08M12.77B5.38%
2026-06-29Invesco Ltd.16.32M7.17B3.02%
2026-06-29Geode Capital Management, LLC15.70M6.90B2.90%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-03-30VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund17.12M7.52B3.17%
2026-03-30VANGUARD INDEX FUNDS-Vanguard 500 Index Fund13.68M6.01B2.53%
2026-06-29Invesco QQQ Trust, Series 111.46M5.03B2.12%
2026-05-30SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF9.79M4.30B1.81%
2026-06-29Income Fund of America7.76M3.41B1.44%
2026-06-29iShares Trust-iShares Core S&P 500 ETF7.45M3.27B1.38%
Dividend
DividendDate
2.522026-08-21
2.522026-05-15
2.522026-02-13
2.382025-11-21
2.382025-08-22
2.382025-05-16
Split
SplitDate
2 : 11999-11-22
2 : 11999-03-01
2 : 11995-08-16
3 : 11991-09-11
2 : 11990-08-13